Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Pfizer Closes in on a Major Spinoff

By George Budwell - Jul 29, 2019 at 9:07AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharmaceutical giant will reportedly combine its legacy products business with generic drug major Mylan.

Big pharma titan Pfizer ( PFE -3.00% ) is on a roll. Since swapping out former CEO Ian Read for the more forward-thinking Albert Bourla earlier this year, the company has advanced a proposed joint venture with GlaxoSmithKline designed to dump its underperforming consumer healthcare unit, and acquired the promising oncology company Array BioPharma in a cost-effective $11.4 billion deal. Now, Pfizer is on the cusp of finally addressing its biggest overhang -- its vast portfolio of declining former star medicines.  

Over the weekend, The Wall Street Journal reported that Pfizer is negotiating a deal to combine its off-patent drug business with generic drug giant Mylan ( MYL ) in an all-stock transaction. Mylan shareholders will reportedly own approximately 43% of the new venture, and Pfizer's shareholders will own the other 57%. Pfizer will also walk away with a healthy $12 billion in proceeds from the sale of debt. The new company will be renamed and rebranded after the deal officially closes. 

A yellow road sign that reads "Change Just Ahead" set against a blue cloudy sky.

Image Source: Getty Images.

Should investors cheer -- or jeer -- this planned spin-off?

A win-win situation 

This proposed transaction has all the ingredients to be a major win for both companies. Mylan's business has been faltering of late due to a variety of headwinds. This deal would give the company a slate of proven revenue generators like Lipitor and Viagra that should greatly beef up its free cash flows on a forward-looking basis.

Equally as critical, embattled CEO Heather Bresch would reportedly be replaced by Michael Goettler, who currently heads up Upjohn. Wall Street has long been clamoring for a change in leadership at Mylan, given that the company has thus far failed to get out ahead of any of its fundamental problems. Goettler's appointment as CEO should appease most of Mylan's biggest critics.    

Pfizer, on the other hand, has been looking for a way to unload its legacy products business for what seems like forever. Even under former CEO Ian Read, it was searching for a strategy to divest itself of its off-brand drug segment so that it could spotlight its newer products like the breast cancer medicine Ibrance and the mega-blockbuster vaccine Prevnar 13. This transaction would certainly tick that all-important box, and transform Pfizer into a smaller, more nimble, growth-oriented company. 

First a sale, and then...a purchase?

Assuming this spinoff goes off without a hitch, Pfizer will almost certainly follow it up by pursuing a bolt-on acquisition to shore up its innovative products business. While most analysts will likely point to oncology as the drugmaker's preferred hunting ground, it also might turn to orphan medicines. Pfizer, after all, already has a formidable oncology portfolio following the Array deal, and there are a number of extremely attractive takeover targets in the rare disease space right now. 

Which rare disease companies might Pfizer target? BioMarin Pharmaceutical, Sarepta Therapeutics, and Vertex Pharmaceuticals ( VRTX -0.27% ) are three names to keep an eye on. Each sports at least one franchise-level medicine, as well as a variety of high-value clinical assets. Vertex, for instance, has a virtual monopoly in cystic fibrosis, and also aims to make inroads in the muscular dystrophy market via its recent gene-editing collaboration with Crispr Therapeutics. Those are two enormous markets that could lure a growth-hungry suitor like Pfizer.

Bottom line: This proposed Mylan transaction only sets the table for Pfizer to make additional business development moves in the near future. The drugmaker, after all, clearly needs at least one more big bolt-on acquisition like Vertex -- or perhaps a handful of smaller tuck-in deals -- to truly flesh out its innovative medicines business.  

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$53.04 (-3.00%) $-1.64
Viatris Inc. Stock Quote
Viatris Inc.
MYL
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
VRTX
$204.45 (-0.27%) $0.55

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
634%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.